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Only Apolipoprotein E polymorphisms have been consistently associated with the risk of late-onset Alzheimer disease (LOAD), but they
represent only a minority of the underlying genetic effect. To identify additional LOAD risk loci, we performed a genome-wide associ-
ation study (GWAS) on 492 LOAD cases and 498 cognitive controls using Illumina’s HumanHap550 beadchip. An additional 238 cases
and 220 controls were used as a validation data set for single-nucleotide polymorphisms (SNPs) that met genome-wide signiﬁcance. To
validate additional associated SNPs (p < 0.0001) and nominally associated candidate genes, we imputed SNPs from our GWAS using
a previously published LOAD GWAS1 and the IMPUTE program. Association testing was performed with the Cochran-Armitage trend
test and logistic regression, and genome-wide signiﬁcance was determined with the False Discovery Rate-Beta UniformMixture method.
Extensive quality-control methods were performed at both the sample and the SNP level. The GWAS conﬁrmed the known APOE asso-
ciation and identiﬁed association with a 12q13 locus at genome-wide signiﬁcance; the 12q13 locus was conﬁrmed in our validation data
set. Four additional highly associated signals (1q42, 4q28, 6q14, 19q13) were replicated with the use of the imputed data set, and six
candidate genes had SNPs with nominal association in both the GWAS and the joint imputated data set. These results help to further
deﬁne the genetic architecture of LOAD.Introduction
Alzheimer Disease (AD [MIM 104300]) is the leading cause
of dementia in the elderly and has a complex etiology, with
strong genetic and environmental determinants. Apolipo-
protein E (APOE [MIM 107741]) is the single most signiﬁ-
cant genetic risk factor identiﬁed for late-onset AD
(LOAD) and was identiﬁed as a risk gene primarily through
genetic mapping.2–5 Though APOE has been universally
conﬁrmed as a risk gene for LOAD, the risk polymorphism
is neither necessary nor sufﬁcient to cause AD, given that
as much as 50% of the genetic-risk effect remains unex-
plained.6 Efforts to identify additional AD loci have
primarily taken the form of genome-wide linkage scans
in multiplex families (two or more individuals with AD)
and candidate-gene association studies. Though linkage
scans were instrumental in detecting the effect of the
APOE gene, they suffer from low resolution (signals often
cover over 30 million base pairs) and have low power to
detect smaller signals.7 Candidate-gene studies use
increased resolution, but their ability to replicate positive
results has been both difﬁcult and inconsistent.8
With the advent of genome-wide association studies
(GWAS), we can now interrogate the entire genome with
increased resolution and power. GWAS have already been
completed for a variety of complex genetic diseases, with
varying degrees of success.1,9–15 Two published GWAS
have examined LOAD, and both studies13,14 convincingly
conﬁrmed the association of APOE to LOAD (p value ¼The1.0 3 1039 and 2.3 3 1044, respectively), but neither
has shown genome-wide signiﬁcance at any SNP unlinked
to APOE. This suggests that the remaining LOAD risk loci
must be of small effect.
To identify the loci underlying the remaining genotypic
effect, we present here a GWAS of LOAD, with 492 cases
and 498 controls, using the Illumina HumanHap 550 bead-
chip. SNPs signiﬁcant at the genome-wide level were
genotyped in an independent validation data set. SNPs
with strong association (p values < 0.0001) and nominally
associated SNPs (p values < 0.05) in and near candidate
genes were examined in a previous GWAS of AD (by
Reiman et al.1) using an imputation procedure.16
Subjects and Methods
Ascertainment and Genotyping
Our analysis uses a clinic-based case-control design. The sample
set is derived from the Collaborative Alzheimer Project (CAP, the
Miami Institute for Human Genomics at the University of Miami
Medical Center and the Center for Human Genetics Research at
Vanderbilt University Medical Center). The CAP data set utilized
for this report is independent from previously published data sets.
After complete description of the study to the subjects, written
informed consent was obtained from all participants, in agree-
ment with protocols approved by the institutional review board
at each contributing center. For inclusion, each LOAD affected
individual met the NINCDS-ADRDA criteria for probable or deﬁ-
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age.17 Subjects’ AAO for LOADwas determined from speciﬁc probe
questions within the clinical history provided by a reliable family
informant or from documented signiﬁcant impairment in the
medical record. Cognitive controls were spouses, friends, and
other biologically unrelated individuals who were frequency
matched by age and gender to the cases and were from within
the same clinical catchment areas. All cognitive controls were
examined, and none showed signs of dementia in clinical history
or upon interview. Additionally, each cognitive control had a docu-
mentedMini-Mental State Exam (MMSE) scoreR 27 or a Modiﬁed
Mini-Mental State (3MS) Exam scoreR 87;18 of the controls, 78%
had documented 3MS Exams and 22% had documented MMSEs.
The preliminary GWAS cohort contained a total of 1086 individ-
uals of European descent. There were 529 LOAD cases, average
age 71.7 years at onset (þ/ 7.2 years), and 557 cognitive controls,
average age 74.4 years at exam (þ/ 5.9 years). Each group was
63.5% female.
From this preliminary GWAS cohort, we genotyped 1049 indi-
viduals (518 cases and 531 controls; Table 1). After genotyping
and before the statistical analysis, samples had to pass a stringent
set of quality control tests, so that the integrity of the genetic data
was ensured. The ﬁnal GWAS data set analyzed contains a total of
988 individuals of European descent. There are 492 LOAD cases,
average age 72.9 years at onset (þ/ 6.6 years), and 496 cognitive
controls, average age 74.3 years at exam (þ/ 6.5 years). Cases are
61% female, and controls are 63% female.
The validation data set consisted of 238 LOAD cases and 220
controls—independent of the preliminary cohort—that were
subjected to the same inclusion criteria as those in the GWAS
data set. The cases averaged 67.7 years AAO (þ/ 8.6 years), and
the controls averaged 70.5 years age at exam (þ/ 6.5).
Genotyping
We extracted DNA for individuals ascertained by the CAP by using
Puregene chemistry (QIAGEN, Germantown, MD, USA). We
performed genotyping using the Illumina Beadstation and the
Illumina HumanHap 550 beadchip, following the recommended
conditions, with the exception that we required the more conser-
vative gencall score of 0.25. Genotyping efﬁciency was greater
than 99%, and quality assurance was achieved by the inclusion
of two CEPH controls that were genotyped multiple times. The
lab was blinded to affection status and quality-control samples.
The ABI 7900 Taqman system was used for generating APOE
genotypes corresponding to allele combinations at SNP þ3937/
rs429358 and SNP þ4075/rs7412.
Sample-Quality Control
After genotyping, samples were subjected to a battery of quality-
control tests. One measure of the overall quality of a sample’s
data is sample efﬁciency; the proportion of valid genotype calls
to attempted calls within a sample. Samples with efﬁciency less
than 0.98 were dropped from the analysis. Many of these samples
were previously genotyped on the Illumina Goldengate and/or
ABI Taqman platforms for SNPs that were in the GWAS (80% of
samples were previously typed at 100 or more SNPs; average ¼
346, median ¼ 428). This duplication validates that the sample
was correctly acquisitioned and that the Inﬁnium II assay was
accurate. Samples with less than 90% genotype-concordance rates
on 100 or more previously typed SNPs were dropped from the
analysis. Reported gender and genetic gender were examined
with the use of X-linked SNPs; inconsistent samples were dropped36 The American Journal of Human Genetics 84, 35–43, January 9, 2from the analysis. Relatedness between samples was tested via the
program Graphical Representation of Relatedness (GRR),19 and
related samples were dropped from the analysis.
A set of 3500 independent SNPs (not in strong linkage disequilib-
rium [LD], r2 < 0.16) spread evenly across the autosomal chromo-
somes were analyzed in STRUCTURE20 for evidence of population
substructure (burn in: 1000, iterations: 20,000). In addition to
this ﬁrst run, we ran 250 SNPs with twice the number of iterations.
We also used the program EigenStrat to look for population
substructure. EigenStrat is a principle-components-analysis
program that utilizes eigenvalues to investigate substructure and
to potentially correct for it.21 A set of 20,000 SNPs across the
genome was used.
SNP-Quality Control
SNPs were subjected to several tests for quality before being
analyzed. Genotypes were ﬁrst recalled on the basis of our own
data, per Illumina’s recommendations. Recalling corrects missed
calls due to ill-deﬁned HapMap clusters and eliminates SNPs for
which the platform is inconsistent. Only samples with efﬁciency
greater than 0.98 were used for redeﬁning the genotype clusters.
SNP efﬁciency is calculated as the percentage of samples that
have genotype calls for a given SNP. All SNPs with less than 90%
efﬁciency were dropped from the analysis. SNPs with MAF <
0.005 were dropped, because even under highly optimistic condi-
tions (high risk ratio, direct ascertainment of the disease locus),
these SNPs have 50% power at best. To reduce error, we subjected
SNPswithMAF< 0.10 to amore stringent efﬁciency cutoff of 99%.
SNPs could have signiﬁcant Hardy-Weinberg disequilibrium statis-
tics for legitimate biological reasons and could have even been
used for disease inference.22,23 Laboratory-process errors typically
lead to very extreme disequilibrium, so SNPs were only dropped
when the HWD statistic was signiﬁcant at the p < 106 level.
HWD statistics were calculated with the Fisher’s exact test in the
PLINK package.24
Association Analysis
Association analysis was performed with the use of the Cochran-
Armitage trend test for association.25 This method tests for a linear
Table 1. GWAS Sample Information
All Cases Controls
Total 988 492 496
Male:Female
Ratio
372:616 (1:1.66) 180:312 (1:1.73) 192:304 (1:1.58)
AAOa or AAEb 72.9 (þ/ 5.5) 74.2 (þ/ 5.6)
APOE /c
carriers
547 (55.7%) 169 (34.5%) 378 (76.6%)
APOE /4d
carriers
339 (34.5%) 234 (47.9%) 105 (21.3%)
APOE 4/4e
carriers
96 (9.8%) 86 (17.6%) 10 (2.0%)
Efficiencyf 99.8% 99.8% 99.8%
A description of the GWAS analysis cohort.
a Age at onset (cases).
b Age at exam (controls).
c Samples with no APOE e4 alleles.
d Samples with only one APOE e4 allele.
e Samples with two APOE e4 alleles.
f Percentage of successfully genotyped SNPs among those attempted.009
trend in the number of alleles at a single locus. That is, two copies
of an allele have more of an effect than one copy, which in turn
has more of an effect than no copies. The effect is in the same
direction for each genotype. This test is equivalent to the score
statistic from a logistic-regression model with no covariates. In
addition to the standard trend test, we performed logistic regres-
sion, with APOE status, age at onset (cases) or exam (controls),
and gender as covariates. All analyses were performed via PLINK.24
APOE status was designated as the number of e4 alleles. A genome-
widemultiple-testing correctionwas applied with a false-discovery
rate, with the use of the beta-uniform distribution.26 SNPs with
FDR q values less than 0.20 were declared signiﬁcant. Initial hap-
lotyping was performed with the Haploview software27 using the
conﬁdence-interval-based block deﬁnitions,28 and follow-up was
performed with the Haplo.Stats software.29,30
Imputation Analysis
The software IMPUTE16was used for imputing genotype data. Both
our data and the data from the previous GWAS1 were imputed,
independently, to a HapMap reference of over 2.5 million SNPs.
Individual genotypes with probability less than 0.90 were not
included, and SNPs missing > 10% of genotypes within either
data set were dropped from the joint analysis. Joint analysis was
performed with PLINK.24 Association testing was performed in
PLINK, with logistic regression, with an indicator variable of study
of origin included as a covariate.
Results
Genotypes were initially generated on 518 LOAD cases and
531 cognitive controls for 555,000 SNPs. Stringent quality-
control criteriawere required for all samples andmarkers.Of
the initial1049 samples, 988met thequality-control criteria
(492 cases, 498 controls; average genotyping efﬁciency >
99.8%). There were 31 samples (3%) dropped because their
efﬁciencies were less than 98%, and 17 samples were drop-
ped because their concordance rates were less than 90%.
Nine samples were dropped because the genotypic gender
disagreed with the clinical information (ﬁve males that
tested female, four females that tested male), and three
samples were dropped because of their relatedness to other
samples. One additional sample was dropped for clinical
reasons. Of the 555,000 SNPs, only 23,000 (4%) were drop-
ped from the analysis (averageminor-allele frequencyof the
remaining SNPs ¼ 0.246). Samples were tested for popula-
tion substructure, and none was found. In STRUCTURE,
there were no samples that consistently clustered in the
same groups and there was no observation of bimodality
or outliers in the plots. In Eigenstrat, the top PCA compo-
nents accounted for only a small percentage of variation
(< 3%) and there was no bimodality or outliers in the plots
of the top principal components.
There were 38 SNPs with uncorrected p values< 0.00005
for association to LOAD using the Cochran-Armitage trend
test, six of which were in or near the APOE gene (Table 2;
complete results in Figure 1), including the top three
(not shown). The LOAD association at APOE represents a
positive control. The remaining 32 SNPs span the genome,The Arepresenting 19 distinct signals across 16 chromosomes.
There was little change in this list when logistic regression
with covariates was applied instead of the trend test (sex,
age at onset or at exam, and APOEe4-carrier status as cova-
riates). The majority of these signals (12 of 19) lie in
regions that have previously shown genetic linkage to
LOAD through other studies.8
The most signiﬁcant non-APOE SNP was rs11610206 on
12q13 (45.92Mb). This SNPmet genome-wide signiﬁcance
criteria with the use of the False Discovery Rate-Beta
UniformMixture (FDR-BUM)26multiple-testing-correction
criteria. The uncorrected p value was 1.93 3 106 (FDR ¼
0.17). Because this SNP met our signiﬁcance criteria, we
genotyped the marker in an independent data set. The
marker was signiﬁcant in our independent replication
data set of 238 cases and220controls (p¼0.0496). Theasso-
ciationwas in the samedirection, and the joint analysis had
a p value of 3.452 3 107, nearly an order of magnitude
more signiﬁcant than in the initial data set. There is some
mild LD structure in this region, but a haplotype analysis
Table 2. Single-Nucleotide Polymorphisms with a p Value
Less Than 5E5
SNP Chr. BPa p Value Gene Role
rs1415985 1 49,703,336 1.23E05
rs11205641 1 49,957,662 8.41E06
rs4926831 1 50,062,688 1.23E05
rs9659092 1 50,216,176 4.54E06
rs11583200 1 50,332,407 1.83E05
rs11683103 2 34,766,354 8.58E06
rs2119067 2 165,835,529 4.38E05
rs10184275 2 165,836,174 2.20E05
rs2681411 3 123,268,321 4.21E05 CD86 Intron
rs12639920 4 42,107,444 4.85E05 ATP8A1 Downstream
rs3807031 6 30,141,863 1.16E05 PPP1R11 Promoter
rs929156 6 30,247,678 1.69E05 TRIM15 Intron
rs11754661 6 151,248,771 2.01E05 MTHFD1L Intron
rs9455973 6 168,325,855 4.47E05
rs6942930 7 1,518,946 1.61E05
rs2039461 9 20,135,988 3.48E05
rs7893928 10 44,398,949 2.31E05
rs11610206* 12 45,925,793 1.43E06 FAM113B Downstream
rs2387100 13 27,324,759 3.82E05
rs9544105 13 75,456,154 5.41E06
rs659628 13 76,361,237 4.46E05 KCTD12 Promoter
rs12146962 14 32,450,849 7.25E06
rs4555132 15 95,740,242 3.08E05
rs1480090 15 96,533,184 3.52E05
rs1383139 15 96,535,200 3.48E05
rs1402627 18 4,123,739 4.42E05
rs4459653 19 49,291,455 8.00E06 ZNF224 Intron
rs4802207 19 49,292,217 9.23E06 ZNF224 Intron
rs3746319 19 49,304,071 2.96E05 ZNF224 Coding exon
rs2061332 19 49,305,501 3.93E05 ZNF224 Downstream
rs6059244 20 29,474,144 4.76E05
rs2180566 20 29,482,515 3.80E05 DEFB123 Promoter
SNPs in the GWAS with p values < 5 3 105, based on 492 cases and 496
controls. p values are calculated with the Cochran-Armitage trend test and
are uncorrected for multiple testing. APOE-linked SNPs have been removed.
Asterisk indicates the SNP that met genome-wide significance.
a BP indicates position in base pairs.merican Journal of Human Genetics 84, 35–43, January 9, 2009 37
Figure 1. Plot of GWAS Results
This plot shows the results of our GWAS. The results are reported as –log10(p value) by genomic position. The horizontal line indicates the
0.05 p value cutoff.of this and surrounding SNPs does not reveal any stronger
association than that of the rs11610206 SNP alone. There
are a number of genetic linkage results on 12q13.31–34 In
particular, the broad linkage signals observed on 12q were
narrowed considerably in the Liang et al. study34 using an
ordered-subset analysis (44 Mb–48 Mb). This association
lies directly under the Liang et al. linkage signal and repre-
sents a conﬁrmation of that signal in an independent data
set; no individuals from the families in the Liang et al. study
were used in our case-control cohort. Other than three of
the APOE-linked SNPs, there were no additional loci that
met the FDR threshold.
Tovalidate additional associatedSNPs,weusedan imputa-
tionapproach.BothourGWASand thepreviouslypublished
GWAS1were imputed to aHapMap referencewith the use of
IMPUTE,16 andthecommonSNPswere thebasis for compar-
ison. We ﬁrst compared the strongly associated results from
each study (p < 0.0001), and we then examined nominally
associated markers within known candidate genes.
Among the top signals in the GWAS, there were four that
showed association in both studies (Table 3). Two of these
signals, 1q42 and 19q13, are within genes. The 1q42 signal
(rs12044355) has the following p values: pB ¼ 0.026; pR ¼
0.000044; pJ¼ 0.0000020 (in which pB is the p value in our
data set, pR is the p value in the Reiman
1 data set, and pJ is
the p value in the joint analysis). It is within an intron of
the disrupted in schizophrenia 1 (DISC1) gene.
The 19q13 signal is in andnear exon6of zinc ﬁnger protein
224 (ZNF224 [MIM194555]). Twoof the associatedmarkers
(rs4508518 and rs3746319) are within the exon. The ﬁrst,
rs4508518 (pB ¼ 0.000039, pR ¼ 0.0082, pJ ¼ 0.0000092),
is a codingbut synonymouspolymorphism,whereas the se-
cond (rs3746319; pB¼ 0.000036, pR¼ 0.01, pJ¼ 0.000011)38 The American Journal of Human Genetics 84, 35–43, January 9, 2leads to a missense mutation. The ZNF224 signal is 800 kb
proximal to APOE but is not in LD to APOE (Table 4). Addi-
tionally, logistic regressionof ourdata showed that the asso-
ciation of the ZNF224 signal was not greatly diminished
when APOEe4-carrier status was included as a covariate.
The rs20612332 SNP has a p value equal to 0.000030
without APOEe4-carrier status as a covariate and a p value
equal to 0.000038 with carrier status as a covariate. This
conﬁrms that the signal is independent of APOE.
The two other signals replicated in both data sets are not
in known genes. The gene nearest the chromosome 6
signal is branched chain keto acid dehydrogenase E1, beta
polypeptide (BCKDHB [MIM 248611]) but is over 800 kb
proximal to the SNP. The chromosome 4 signal is 200 kb
proximal to protocadherin 18 (PCDH18 [MIM 608287]), a
protocadherin precursor that is thought to play a role in
cell-cell connections in the brain.
Inaddition to these tophits,ninecandidategenes fromthe
over500genes intheAlzGenecandidate-gene list1haveSNPs
with nominal association in both GWASs (Table 5). These
genes (ADAM12, CSF1, GBP2, KCNMA1, NOS2A, SORCS2,
SORCS3, SORL1, WWC1 [MIM 602714, 120420, 600412,
600150, 163730, 606284, 606285, 602005, 611675, respec-
tively]) had p values ranging from 0.003 to 0.05 in the indi-
vidual GWAS and from 0.0001 to 0.01 in the joint analysis.
Of the 21 nominally associated SNPs, 19 were intronic, and
the remaining 2 are downstream from the gene.
Discussion
We have shown genome-wide association of the SNP
rs11610206 with LOAD and have validated this signal in009
Table 3. Top Association Signals that Were Replicated in Both GWAS
SNP Chr. BPa Type PB
b PR
c PJ
d Gene Role
rs12044355 1 229,910,970 R 3.90E-05 0.008216 9.20E-06 DISC1 Intron
rs1425967 4 138,508,340 R 3.90E-05 0.01052 1.25E-05
rs4416533 4 138,546,322 I 3.61E-05 0.0101 1.13E-05
rs13213247 6 81,572,755 R 4.73E-05 0.01587 2.40E-05
rs4508518 19 49,303,260 I 0.02627 4.37E-05 1.95E-06 ZNF224 Coding exon
rs3746319 19 49,304,071 B 6.05E-05 0.02326 3.01E-06 ZNF224 Coding exon
rs2061332 19 49,305,501 B 6.19E-05 0.03786 4.91E-06 ZNF224 Downstream
rs2061333 19 49,306,048 I 0.01745 2.51E-05 1.51E-06 ZNF224 Downstream
SNPs in either GWAS with a p value< 0.0001 that was replicated in the other GWAS. p values calculated are uncorrected for multiple testing. ‘‘Type’’ refers to
how the marker was genotyped; Type B markers were genotyped in the Beecham GWAS and imputed in the Reiman samples, Type R markers were genotyped
in the Reiman GWAS and imputed in the Beecham samples, and Type I markers were imputed in both GWAS.
a BP indicates position in base pairs.
b PB indicates the p values from this study.
c PR indicates the p values from the study by Reiman et al.
1
d PJ indicates the p values from the joint analysis.an independent case-control data set. This provides strong
evidence for a risk locus on 12q13. The SNP is not in
a known gene but is less than 10 kb from the hypothetical
gene FAM113B. Additionally, there are a number of nearby
candidate genes, such as the vitamin D (1,25- dihydroxyvita-
min D3) receptor (VDR [MIM 601769]) and adhesion molecule
with Ig-like domain 2 (AMIGO2). VDR is the most appealing
of the candidate genes. There has been association with
VDR reported,35 and VDR has been associated with
memory performance.36 There is no known connection
between our top SNP and VDR, but the region between
the two is largely uncharacterized; it is possible that the
top SNP could be in a long-range regulatory element that
inﬂuences VDR.
It is of note that the rs11610206 SNP was not imputed in
the Reiman1 data with enough conﬁdence to allow inclu-
sion in the imputation analysis. This demonstrates one
of the weaknesses of imputation. If there is not strong
LD between a genotyped SNP and an untyped SNP of
interest, the untyped SNP will not be imputed with high
conﬁdence. In this case, there is not extended LD around
rs11610206, so the nearest SNPs in the Reiman GWAS
were not sufﬁciently informative for imputation. This
same phenomenon was seen at the APOE locus. The two
data sets did not share any SNP near APOE, and nearbyTheHapMap SNPs were not imputed with conﬁdence. In the
end, the signal at APOE—highly signiﬁcant in each indi-
vidual GWAS—is missed entirely in the joint imputation
analysis unless quality control standards are lowered.
Indeed, nearly 20% of the top SNPs from our GWAS failed
to be imputed in the Reiman data.
Four of the top hits among the GWAS were validated in
the imputation analysis. The 1q42 and 19q13 signals are of
particular interest. The 1q42 signal resides in the DISC1
gene, a gene that has been associated with schizophrenia
and has links to bipolar disorder, depression, and cognitive
function.37–41 The 19q13 signal lies in the exon of the
ZNF224 gene, and several of the SNPs were coding SNPs,
including one missense mutation. Although this is not
the ﬁrst report of a non-APOE signal on 19q13,42,43 it is
the ﬁrst time the ZNF224 gene has been implicated
speciﬁcally.
There were eight candidate genes from the AlzGene list
with SNPs associated in both GWASs. Principal among
these genes is sortlin-related receptor (SORL1), a gene that
has received much attention in LOAD genetics. SORL1
(alternatively LR11 or SorLA) has been associated with
LOAD in a variety of populations.44–47 Replication has
been inconsistent,45,48,49 and it is thought that there could
be extensive locus and allelic heterogeneity involved.44,50Table 4. LD between ZNF224 SNPs and APOE-Linked SNPs
Gene SNP Position rs4802207 rs3746319 rs2061332 rs2075650 rs8106922 rs405509 rs439401
ZNF224 rs4459653 19: 49,305,501 0.94 0.92 0.92 0 0.01 0.01 0
rs4802207 19: 49,306,048 0.95 0.95 0 0.01 0.01 0
rs3746319 19: 49,304,071 1.00 0 0.01 0.01 0
rs2061332 19: 49,303,260 0 0.01 0.01 0
APOE rs2075650 19: 50,087,459 0.16 0.24 0.08
rs8106922 19: 50,093,506 0.60 0.08
rs405509 19: 50,100,675 0.17
rs439401 19: 50,106,291
LD between the ZNF224 SNPs on 19q13 (rs4459653, rs4802207, rs3746319, rs2061332) and SNPs most linked to APOE on 19q13 (rs2075650, rs8106922,
rs405509, rs439401). Disequilibrium is reported as r2. Position is reported in base pairs. This shows that there is a single ZNF224 signal that is independent
from the APOE signal.American Journal of Human Genetics 84, 35–43, January 9, 2009 39
Table 5. Candidate Genes with SNPs Significant in Both GWAS
Gene SNP Chr. BPa Type PB
b PR
c PJ
d ORe
ADAM12 rs11244841 10 127,824,556 B 0.04379 0.04551 0.003386 1.2180
CSF1 rs7537752 1 110,186,484 R 0.03273 0.0378 0.002087 0.8082
GBP2 rs10922573 1 89,300,401 B 0.01481 0.00854 0.000833 1.2190
GBP2 rs12725861 1 89,278,117 I 0.008497 0.01599 0.000945 1.2170
GBP2 rs6428503 1 89,296,090 B 0.01165 0.00854 0.000665 1.2230
KCNMA1 rs16934131 10 78,407,601 I 0.04519 0.03569 0.003338 1.2210
NOS2A rs11653716 17 23,108,659 I 0.003526 0.007249 0.00014 0.4845
SORCS2 rs3846421 4 7,403,428 B 0.003131 0.0206 0.000117 0.7805
SORCS3 rs10786828 10 106,599,890 B 0.04546 0.03495 0.004627 1.1800
SORCS3 rs7894737 10 106,603,320 I 0.04694 0.04736 0.004345 1.1840
SORL1 rs11218342 11 120,939,638 I 0.04825 0.04859 0.008507 0.5509
SORL1 rs11218343 11 120,940,797 I 0.04825 0.04859 0.008507 0.5509
SORL1 rs1784919 11 120,944,875 I 0.04825 0.04813 0.008433 0.5505
SORL1 rs1792124 11 120,946,730 I 0.04825 0.04813 0.008433 0.5505
SORL1 rs2298814 11 120,930,092 I 0.04825 0.04906 0.008583 0.5513
SORL1 rs3781835 11 120,953,464 B 0.04825 0.03458 0.006237 0.5353
SORL1 rs3781838 11 120,958,727 I 0.03072 0.03314 0.004064 0.5157
SORL1 rs6589885 11 120,931,252 I 0.04825 0.04906 0.008583 0.5513
SORL1 rs720099 11 120,939,003 I 0.04825 0.04859 0.008507 0.5509
SORL1 rs7946599 11 120,928,850 I 0.04825 0.04906 0.008583 0.5513
WWC1 rs12514426 5 167,826,286 I 0.03592 0.004984 0.000928 0.5430
SNPs in candidate genes associated with LOAD in both GWAS and the joint analysis. p values are uncorrected for multiple testing. ‘‘Type’’ refers to how the
marker was genotyped; Type B markers were genotyped in this GWAS and imputed in the Reiman samples, Type R markers were genotyped in the Reiman
GWAS and imputed in the samples from this GWAS, and Type I markers were imputed in both GWAS.
a BP indicates position in base pairs.
b PB indicates the p values from this study.
c PR indicates the p values from the Reiman et al. study.
1
d PJ indicates the p values from the joint analysis.
e OR indicates odds-ratio estimates.There are also multiple studies that show that SORL1
expression is decreased in Alzheimer disease and in the
cognitively impaired brain.51–53 Although there are no
consensus SORL1 mechanisms that confer LOAD risk, it
is known that the SORL1 protein interacts with both
APOE protein and amyloid beta (A4) precursor protein
(APP [MIM 104760]).44,54 The ﬁndings of association in
our GWAS, as well as in the joint analysis with the Reiman
GWAS, further conﬁrm SORL1 as a risk gene for LOAD.
Also among the nominally associated genes are guanylate
binding protein 2, interferon-inducible (GBP2), which is upre-
gulated in the hippocampus in AD and has previously
shown nominal signiﬁcance to AD,55 and the gene WW
and C2 domain containing 1 (WWC1), which has shown
association with AD in a Spanish population.56 WWC1
has also been associated with memory performance based
on a verbal-memory task.57
It is ofnote thatmultiple testing is an issuewith the impu-
tation analysis. There are many tests, because the imputa-
tion provides a dense map; this suggests a more stringent
threshold.However, the tests arehighlycorrelatedasa result
of LD, and there is a priori evidence for the candidate-gene
SNPs, suggesting a more relaxed threshold. Rather than
arbitrarily quantifying a statistical prior or establishing
a highly arbitrary signiﬁcance threshold, we report uncor-
rected p values and look for concordance between the two
GWAS.40 The American Journal of Human Genetics 84, 35–43, January 9, 2We have shown a genome-wide signiﬁcant association
between the 12q13 SNP rs11610206 and late-onset Alz-
heimer disease. This signal was replicated in an indepen-
dent case-control cohort. The region around this SNP is
largely uncharacterized, and further delineation of possible
candidates near this SNP is needed. We have also identiﬁed
four regions (1q42, 4q28, 6q14, 19q13) with strong associ-
ation to AD that were replicated in the imputation analysis,
conﬁrmed the association of SORL1 to LOAD, and validated
a number of candidate genes with nominal association in
both GWAS. Detailed functional examination of these
signals and genes could lead to a better understanding of
the complex pathophysiology of Alzheimer disease.
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